Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Клиническое значение аполипопротеинов А и В

Полный текст:

Аннотация

Оценка и коррекция традиционных параметров атерогенной дислипидемии являются важными, но не достаточными методами наблюдения за прогрессом атеросклероза, в т.ч. коронарного. Для более точной диагностической и терапевтической оценки необходимо определять уровни АпоАI, АпоВ и их отношение, причем, чем ниже АпоВ/АпоАI, тем ниже сердечно-сосудистый риск.

Об авторах

Г. А. Чумакова
Алтайский государственный медицинский университет, Барнаул; Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН, Кемерово
Россия

профессор кафедры госпитальной и поликлинической терапии;

в.н.с. отдела мультифокального атеросклероза

Тел.: 8-903-910-80-40




О. В. Гриценко
Алтайский государственный медицинский университет, Барнаул
Россия
аспирант кафедры госпитальной и поликлинической терапии



Н. Г. Веселовская
Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН, Кемерово; Алтайский краевой кардиологический диспансер, Барнаул
Россия

с.н.с. отдела мультифокального атеросклероза;

врач отделения артериальной гипертонии



Е. В. Вахромеева
Алтайский краевой кардиологический диспансер, Барнаул
Россия
врач клинической лаборатории



А. А. Козаренко
Алтайский государственный медицинский университет, Барнаул; Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН, Кемерово
Россия

н.с. отдела мультифокального атеросклероза;

аспирант



Список литературы

1. Mathieu P, Pibarot P, Després J-P. Metabolic Syndrome: The Danger Signal in Atherosclerosis. Vasc Health Risk Manag 2006; 2(3): 285-302.

2. Olofsson S-O, Wiklund O, Borén J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007; 3(4): 491-502.

3. Baroni MG, Berni A, Romeo S, et al. Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Med Genet 2003; 4: 8.

4. Руководство по атеросклерозу и ишемической болезни сердца. Под редакцией акад Чазова Е.И., чл.- кор. РАМН Кух6арчука В.В., проф. С.А.Бойцова. М.: “MEDIAMEDICA” 2007; 736 с.

5. Gazi I, Tsimihodimos V, Filippatos TD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis 2006; 5: 8.

6. Hübner K, Schwager T, Winkler K, et al. Computational Lipidology: Predicting Lipoprotein Density Profiles in Human Blood Plasma. PLoS Comput Biol 2008; 4(5): e1000079.

7. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (четвертый пересмотр). Кардиоваск тер проф 2009; 6 (приложение 3): 15.

8. Kyung-Hyun Cho, Jae-Ryong Kim. A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation. Exp Mol Med 2009; 41(6): 417-28.

9. Brouillette CG, Anantharamaiah GM, Engler JA, et al. Structural models of human apolipoprotein A-I: critical analysis and review. Biochim Biophys Acta 2001; 1531(1-2): 4-46.

10. Gorshkova IN, Tong Liu, Horng-Yuan Kan, et al. Structure and Stability of Apolipoprotein A-I in Solution and in Discoidal High Density Lipoprotein Probed by Double Charge Ablation and Deletion Mutation. Biochemistry 2006; 45(4): 1242-54.

11. Ожирение и нарушение липидного обмена. Под редакцией акад. РАН и РАМН Дедова И.И., чл. — кор. РАМН Г.А. Мельниченко. М.: “Рид Элсивер” 2010; 264 с.

12. Dao-Quan Peng, Brubaker G, Zhiping Wu, et al. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase mediated loss of function. Arterioscler Thromb Vasc Biol 2008; 28(11): 2063-70.

13. Chetty PS, Mayne L, Lund-Katz S, et al. Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci U S A 2009; 106(45): 19005-10.

14. Ooi EMM, Watts GF, Nestel PJ, et al. Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome. J Clin Endocrinol Metab 2008; 93: 430-7.

15. McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008; 22(4): 321-38.

16. Sharifi F, Mousavinasab SN, Saeini M, et al. Prevalence of metabolic syndrome in an Adult Urban Population of the West of Iran. Exp Diabetes Res 2009; 2009: 136501.

17. Kuo-Liong Chien, Wei J, Chen, Hsiu-Ching Hsu, et al. Segregation analysis of apolipoprotein A1 levels in families of adolescents: A community-based study in Taiwan. BMC Genetics 2006, 7:4doi:10.1186/1471-2156-7-4.

18. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004; 95(8): 764-72.

19. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010; 31(2): 149-64.

20. Ajees AA, Anantharamaiah GM, Mishra VK, et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A 2006; 103(7): 2126-31.

21. Van V, Eck M, Pennings M, Hoekstra M, et al. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005; 16(3): 307-15.

22. Chroni A, Liu T, Gorshkova I, et al. The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type ApoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem 2003; 278(9): 6719-30.

23. Tall AR, Breslow JL, Rubin EM. Genetic disorders affecting plasma high — density lipoproteins. The Metabolic and Molecular Bases of Inherited Disease 2001; 2: 2915-36.

24. Cho KH, Durbin DM, Jonas A. Role of individual amino acids of apolipoprotein A — 1 in the activation of lecinin: Cholesterol acyltransferase and in HDL rearragements. J Lipid Res 2001; 42: 379-89.

25. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001; 108(6): 793-7.

26. Linsel-Nitschke P, Tall AR. HLD as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205.

27. Castellani LW, Nguyen CN, Charugundla S. Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. J Biol Chem 2008; 283(17): 11633-44.

28. Дислипидемии и атеросклероз. Под ред. проф., акад. РАМН Р.Г. Оганова. М.: “ГЭОТАР — МЕДИА” 2009; 160 с.

29. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19 Suppl A: A31-5.

30. Castellani LW, Navab M, Van Lenten BJ, et al. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100(2): 464-74.

31. Kalopissis AD, Pastier D, Chambaz J. Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol 2003; 14(2): 165-72.

32. Williams PT, Krauss RM, Vranizan KM, et al. Effects of WeightLoss by Exercise and by Diet on Apolipoproteins A-I and A-II and the Particle-Size Distribution of High-Density Lipoproteins in Men. Metabolism 1992; 41(4): 441-9.

33. Rocco AG, Mollica L, Gianazza E, et al. A Model Structure for the Heterodimer apoA-IMilano-apoA-II Supports Its Peculiar Susceptibility to Proteolysis. Biophys J 2006; 91(8): 3043-9.

34. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda study. Circulashion 2001; 103(15): 1949-54.

35. Wang L, Sharifi BG. Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic Mice. JACC 2006; 48(7): 1459-68.

36. Franceschini G, Vecchio G, Gianfranceschi G, et al. Apolipoprotein A-IMilano: accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem 1985; 260: 16321-5.

37. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. JACC 2008; 51(11):1098-103.

38. Parolini C, Chiesa G, Gong E, et al. Apolipoprotein A-I and the molecular variant apoA-I (Milano): evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis 2005; 183(2): 222-9.

39. Calabresi L, Canavesi M, Bernini F, et al. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry 1999; 38(49): 16307-14.

40. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 90(17): 2292-300.

41. Kaul S, Rukshin V, Santos R, et al. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003; 107(20): 2551-4.

42. Andrikoula M, McDowell IF. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008; 10(4): 271-8.

43. Harper CR, Jacobson TA. Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change? Mayo Clin Proc 2010; 85(5): 440-5.

44. Richardson PE, Manchekar M, Dashti N, et al. Assembly of Lipoprotein Particles Containing Apolipoprotein-B: Structural Model for the Nascent Lipoprotein Particle Biophys J 2005; 88(4): 2789-800.

45. Jiang ZG, Gantz D, Bullitt E, et al. Defining Lipid Interacting Domains in the N-terminal Region of Apolipoprotein B. Biochemistry 2006; 45(39): 11799-808.

46. Арабидзе Г.Г., Ипатов А.И., Полякова О.В. и др. Аполипопротенин В100 и липопротеид (а) как факторы риска развития острого инфаркта миокарда. Клин фармак тер 2005; 14 (5): 87-9.

47. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259(3): 247-58.

48. Williams K, Tchernof A, Hunt KJ, et al. Diabetes, Abdominal Adiposity, and Atherogenic Dyslipoproteinemia in Women Compared With Men. Diabetes 2008; 57(12): 3289-96.

49. Benn M, Nordestgaard BG, Jensen GB, et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007; 27(3): 661-70.

50. Younis HN, Soran H, Sharma R, et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res 2010; 7(4): 289-95.

51. Superko HR, King S. III Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008; 117: 560-8.

52. Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. JACC 2005; 46(1): 158-65.

53. Yufus S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-52.

54. Millán J, PintóX, Muñoz A, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009; 5: 757-65.

55. Walldius G, Junger I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42(12): 1355-63.

56. Walldius G, Junger I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy — a review of evidence. J Intern Med 2006; 259: 493-519.

57. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006; 259(5): 481-92.

58. Sierra-Johnson J, Somers VK, Kuniyoshi FH, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98: 1369-73.

59. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J 2007; 28: 2637-43.

60. Sniderman AD. The apoB/apoA-I ratio and insulin resistance: sorting out the metabolic syndrome. Eur Heart J 2007; 28: 2563-4.

61. Sierra-Johnson J, Fisher RM, Romero-Corral A, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009; 30(6): 710-7

62. Schmidt C, Fagerberg B, Wikstrand J, et al. АpoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerois 2006; 189(1): 178-85.

63. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med 2006; 259(5): 493-519.


Для цитирования:


Чумакова Г.А., Гриценко О.В., Веселовская Н.Г., Вахромеева Е.В., Козаренко А.А. Клиническое значение аполипопротеинов А и В. Кардиоваскулярная терапия и профилактика. 2011;10(6):105-111.

For citation:


Chumakova G.A., Gritsenko O.V., Veselovskaya N.G., Vakhromeeva E.V., Kozarenko A.A. Clinical role of apolipoproteins A and B. Cardiovascular Therapy and Prevention. 2011;10(6):105-111. (In Russ.)

Просмотров: 8


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)